Mergers & acquisitions
For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
GlaxoSmithKline has decided not to make a play for Pfizer’s consumer health business. The decision came one day after another potential suitor walked away from a potential deal.
Now that Reckitt Benckiser has walked away from a deal, GlaxoSmithKline is now the favorite to acquire Pfizer’s consumer health business.
Platinum Equity submitted a binding offer to Johnson & Johnson to buy LifeScan for $2.1 billion.
Lunbeck is acquiring Prexton Therapeutics BV, a 2012 spinout from Merck KgaA, and its Phase II treatment for Parkinson’s disease.
The Wall Street Journal speculated today that it won’t be long before drug manufacturers start consolidating in order to improve their bottom lines.
Celgene has a deep pipeline and a $69 billion market cap, but it could consider going private in 2019 via a leveraged buyout.
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
U.S. insurer Cigna is acquiring pharmacy benefits manager Express Scripts for approximately $67 billion.
After a huge dry spell in M&A, 2018 is shaping up to be a great year for deal making.
PRESS RELEASES